Variability of clopidogrel response in patients with type 2 diabetes mellitus

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The global prevalence of diabetes mellitus (DM) continues to climb, and is accompanied by an increase in DM associated complications, most often manifesting as coronary heart disease. Platelet dysfunction has been implicated as a central contributor to the increased risk of coronary artery disease in patients with DM, and it is not surprising that the anti-platelet agent, clopidogrel, has been shown to have efficacy in both short and long term outcomes in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. However, accumulating data suggest a clinically relevant sub-optimal clopidogrel response in some patients with DM. The exact mechanism of these observations is not yet fully understood, but appears to be related to reduced concentrations of circulating clopidogrel active metabolite, with less variability in pharmacodynamic and clinical response suggested by the evaluation of newer P2Y12 antagonists, such as prasugrel and ticagrelor. More research is needed to better understand both the pharmacology and clinical consequences of these observations.

Original languageEnglish (US)
Pages (from-to)245-253
Number of pages9
JournalDiabetes and Vascular Disease Research
Volume8
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

clopidogrel
Type 2 Diabetes Mellitus
Diabetes Mellitus
Blood Platelets
Clinical Pharmacology
Diabetes Complications
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Coronary Disease
Coronary Artery Disease
Research

Keywords

  • anti-platelet therapy
  • clopidogrel
  • coronary heart disease
  • Diabetes mellitus
  • prasugrel
  • resistance
  • ticagrelor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{761bc2adc26c4dc1aee59527fe7f9597,
title = "Variability of clopidogrel response in patients with type 2 diabetes mellitus",
abstract = "The global prevalence of diabetes mellitus (DM) continues to climb, and is accompanied by an increase in DM associated complications, most often manifesting as coronary heart disease. Platelet dysfunction has been implicated as a central contributor to the increased risk of coronary artery disease in patients with DM, and it is not surprising that the anti-platelet agent, clopidogrel, has been shown to have efficacy in both short and long term outcomes in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. However, accumulating data suggest a clinically relevant sub-optimal clopidogrel response in some patients with DM. The exact mechanism of these observations is not yet fully understood, but appears to be related to reduced concentrations of circulating clopidogrel active metabolite, with less variability in pharmacodynamic and clinical response suggested by the evaluation of newer P2Y12 antagonists, such as prasugrel and ticagrelor. More research is needed to better understand both the pharmacology and clinical consequences of these observations.",
keywords = "anti-platelet therapy, clopidogrel, coronary heart disease, Diabetes mellitus, prasugrel, resistance, ticagrelor",
author = "Hurst Hall and Subhash Banerjee and McGuire, {Darren K}",
year = "2011",
month = "10",
doi = "10.1177/1479164111420890",
language = "English (US)",
volume = "8",
pages = "245--253",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Variability of clopidogrel response in patients with type 2 diabetes mellitus

AU - Hall, Hurst

AU - Banerjee, Subhash

AU - McGuire, Darren K

PY - 2011/10

Y1 - 2011/10

N2 - The global prevalence of diabetes mellitus (DM) continues to climb, and is accompanied by an increase in DM associated complications, most often manifesting as coronary heart disease. Platelet dysfunction has been implicated as a central contributor to the increased risk of coronary artery disease in patients with DM, and it is not surprising that the anti-platelet agent, clopidogrel, has been shown to have efficacy in both short and long term outcomes in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. However, accumulating data suggest a clinically relevant sub-optimal clopidogrel response in some patients with DM. The exact mechanism of these observations is not yet fully understood, but appears to be related to reduced concentrations of circulating clopidogrel active metabolite, with less variability in pharmacodynamic and clinical response suggested by the evaluation of newer P2Y12 antagonists, such as prasugrel and ticagrelor. More research is needed to better understand both the pharmacology and clinical consequences of these observations.

AB - The global prevalence of diabetes mellitus (DM) continues to climb, and is accompanied by an increase in DM associated complications, most often manifesting as coronary heart disease. Platelet dysfunction has been implicated as a central contributor to the increased risk of coronary artery disease in patients with DM, and it is not surprising that the anti-platelet agent, clopidogrel, has been shown to have efficacy in both short and long term outcomes in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. However, accumulating data suggest a clinically relevant sub-optimal clopidogrel response in some patients with DM. The exact mechanism of these observations is not yet fully understood, but appears to be related to reduced concentrations of circulating clopidogrel active metabolite, with less variability in pharmacodynamic and clinical response suggested by the evaluation of newer P2Y12 antagonists, such as prasugrel and ticagrelor. More research is needed to better understand both the pharmacology and clinical consequences of these observations.

KW - anti-platelet therapy

KW - clopidogrel

KW - coronary heart disease

KW - Diabetes mellitus

KW - prasugrel

KW - resistance

KW - ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=80053080423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053080423&partnerID=8YFLogxK

U2 - 10.1177/1479164111420890

DO - 10.1177/1479164111420890

M3 - Article

C2 - 21933840

AN - SCOPUS:80053080423

VL - 8

SP - 245

EP - 253

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 4

ER -